If you are hanging out at Union Square in San Francisco, you will be infected by the atmosphere of the Biotech Conference (January 9 to 11) that will be held next year, and you will also be exposed to some of the most cutting-edge people in the industry. They are smart and active. They used to be students or postdocs, but now they have created many hot start-up companies. Just like the technology industry, they hope to attract more venture capital companies.
However, the biotech industry has different rules. The venture capital of this industry is usually from older investors (such as 40s and 60s). Therefore, even with the most profound academic background young biomedical scientists still facing the most intense competition for jobs: as research professor for inexperienced small gap, while the pharmaceutical industry is very picky, we all want to hire people with years of work experience people.
According to the National Research Association, the average age of scientists who have their first stable job is 35 to 40 years old. In more detail, when you get your first peer-reviewed sponsorship, on average, you It is already 42 years old. For former bioscientists, employment was not so difficult at the time. In the 1970s, the average age of the first sponsored scientists was 34. In addition, according to the research of Glassdoor in 2014, the biotechnology and pharmaceutical industries have the lowest efficiency in reviewing qualified candidates.
Therefore, the status quo of this industry is discouraging.
However, some young scientists want to solve problems through their own efforts. Ethan Perlstein, who majored in molecular and cellular biology at Harvard University, received a postdoctoral fellowship at Princeton University, but he still felt the embarrassment of job opportunities in the biotech industry. But he was not discouraged. In 2014, Ethan Perlstein founded a company called Perlara to explore drugs for the treatment of rare diseases. At the same time, he has become a spokesperson for young biomedical scientists, aiming to raise the industry's awareness of the imbalance between employment supply and demand.
Two years later, Ethan Perlstein was pleased to have made many biotech graduates aware of the seriousness of employment through their own efforts to better promote themselves in all aspects. Because there are still very few companies that are solving this problem of uneven employment supply and demand, the task of finding a job is still on the shoulders of students.
In fact, in the final analysis, this is a cultural issue. Ethan Perlstein believes that if you don't look for a job as expected by your parents, you will be disappointed.
Nowadays, I have seen many young people have the courage to break the expectations of their parents and turn to pursue the career they want to pursue. They promote themselves in different ways. For example, some people create jobs for themselves and others by becoming entrepreneurs, while others contribute to this field by becoming consultants, venture capitalists, and patent advisors.
Here are 13 young people who are constantly challenging the authority and innovation in the field of biotechnology.
Armon Sharei
As a graduate student at MIT, he initially worked for Klavs Jensen and Bob Langer. He and others have studied a new type of "compression" that directly pours materials into cell fluids. This technology has been a big problem in the pharmaceutical industry. Today, Armon Sharei is the co-founder and CEO of SQZ Biotech, based in Cambridge. His contact with Bob Langer has given him a lot of venture capital opportunities for SQZ. For example, in July 2015, SQZ's A-round investment received $5 million in capital. This financing is rare in the biotech industry, especially if the CEO of the company being invested is less than 30 years old.
But Armon Sharei partner Amy Schulman, as co-executive chairman, has alleviated the concerns of many investors, who don't want to put all their chips on young people who may not be so cautious. A year later, SQZ continued to develop and received $2.4 million in Series B financing.
According to Amy Schulman, a partner at Armon Sharei, “Sharei is a unique and outstanding young man. He is very aggressive. When I first saw him, I asked him what his dream was. He said he wanted to His doctoral thesis research was put into practice and then helped the patient. And he did the same."
Hot Sale Portable Household Spe Pem Electrolysis Gas Hydrogen Breathing Inhalation Device Pure Water Electrolyzer Hydrogen Production Generator
Japanese Hydrogen Inhaler,Water Electrolysis Hydrogen Generator,Hydrogen Production Machine,Brown Gas Generator,Hydrogen Inhalation Machine
A hydrogen inhaler is a device that delivers hydrogen gas for inhalation. Hydrogen gas is considered to have potential health benefits due to its antioxidant and anti-inflammatory properties. The inhaler typically contains a chamber that generates hydrogen gas by electrolysis of water or by using hydrogen-rich tablets or cartridges. When the user inhales through the device, they can potentially benefit from the therapeutic effects of hydrogen gas. Some claimed benefits of hydrogen inhalation include reducing oxidative stress, inflammation, and improving athletic performance. However, further research is needed to fully understand the potential benefits and risks associated with hydrogen inhalation. It is important to consult a healthcare professional before using any new health device or treatment.
What Is Hydrogen?
1. Hydrogen is a chemical element, the first on the periodic table.
Is Hydrogen Safe?
1. Reduce oxidative damage
Japanese Hydrogen Inhaler,Water Electrolysis Hydrogen Generator,Hydrogen Production Machine,Brown Gas Generator,Hydrogen Inhalation Machine
Shenzhen Guangyang Zhongkang Technology Co., Ltd. , https://www.szlighttherapymachine.com